Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Autozone Inc (AZO) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Autozone IncTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

Autozone Inc vs Zimmer Biomet Holdings Inc — how do they compare? Autozone Inc trades at $2,980 (market cap $49.50B), while Zimmer Biomet Holdings Inc trades at $90.17 (market cap $17.61B). The key difference: Autozone Inc is far larger — about 2.8× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.05% dividend while Autozone Inc pays none. Which is the better fit depends on your goals.

AZOZBH
Market Cap
$49.50B$17.61B
Sector
Consumer CyclicalHealth
52-Week High
$4.35K$107.71
52-Week Low
$2.94K$79.58
Enterprise Value
$61.88B$24.66B
Dividend Yield
1.05%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Autozone Inc

AutoZone (AZO) trades at $3,078.98, up 0.21% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company reported mixed recent earnings, beating in Q1 2026 but missing in Q3 2025, with revenue growing to $18.94B in 2025. Analyst sentiment remains strongly positive with a 72.73% buy rating and a consensus price target of $3,740, though recent news highlights stock volatility and competitive pressures.

The outlook for AZO is supported by solid fundamentals, including a 12.4% net income margin and aggressive share buybacks, but risks include slowing profit margin trends and bearish technical indicators. Upside potential exists if the company meets Q2 2026 EPS expectations of 54.51, though investors should monitor same-store sales growth and international expansion execution.

Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) trades at $94.08, up 3.0% in the past 24 hours, near its consensus price target of $97.67. The stock shows bullish technical signals with strong moving average support and has consistently beaten earnings estimates in recent quarters. Revenue grew to $8.23B in 2025, though net income margin declined to 8.56%. Recent corporate developments include expansion in Asia Pacific and a planned $1 billion share repurchase program in 2026.

ZBH presents a balanced outlook with steady revenue growth and shareholder returns via dividends and buybacks, but faces risks from margin compression and rising debt. Analyst sentiment is mixed with 40% buy ratings, suggesting moderate upside potential with caution around profitability trends and competitive pressures in the medical device sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Autozone Inc

AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.

Read more on AZO

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH